- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07657182
A Prospective, Randomized, Assessor-Blinded, Multicenter Study Comparing Avance Nerve Graft and Autograft for Functional Recovery Following Mixed and Motor Peripheral Nerve Reconstruction (Nerve-RESTORE℠)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Type d'étude
Inscription (Estimé)
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
- Nom: Stacy Arnold
- Numéro de téléphone: (386) 462-6800
- E-mail: clinicalresearch@axogeninc.com
Sauvegarde des contacts de l'étude
- Nom: Hayley Nicolosi
- Numéro de téléphone: (386) 462-6800
- E-mail: hnicolosi@axogeninc.com
Lieux d'étude
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46260
- Recrutement
- OrthoIndy
-
Contact:
- Melanie Glover
- Numéro de téléphone: 317-802-2880
- E-mail: mglover@orthoindy.com
-
Chercheur principal:
- Brandon Smetana, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
Study Participant Criteria
- Be ≥ 18 years of age at the time of consent;
- Willing and able to comply with all aspects of the treatment and evaluation schedule over a 24-month duration;
Provide documented Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved informed consent prior to initiation of any study procedures;
Injury/Repair Criteria for Each Nerve
Primary or secondary nerve injury repair with sural nerve autograft or Avance Nerve Graft for fully transected reconstruction of the following upper extremity mixed and/or motor nerve(s):
- Median nerve: proximal nerve stump within 20 cm from the center point of the thenar eminence and distal to the crease of the elbow;
- Anterior interosseous nerve;
- Median nerve recurrent motor branch;
- Radial nerve: proximal nerve stump within 20 cm of the center of the forearm (midpoint between the tip of the olecranon and the styloid process) and distal to the mid-humerus;
- Posterior interosseous nerve.
- Zone of injury of eligible nerve(s) resectable to healthy nerve both distally and proximally and within the anatomical regions of Inclusion Criterion #4;
- In study participants with multiple eligible nerve repairs, repair of all eligible nerves completed with the same study treatment, either Avance Nerve Graft or sural nerve autograft;
- Measured nerve gap(s) following resection > 25 mm;
- Nerve(s) repaired ≤ 120 days post injury;
- Undergo coaptation on both the proximal and distal portion of the nerve gap(s) per the USPI for Avance Nerve Graft and per standard of care for sural nerve autograft; and
- Either treatment method, Avance Nerve Graft or sural nerve autograft, is a viable option for all eligible nerve repair(s) (i.e., volume of injured nerve[s] does not exceed availability of sural nerve autograft for reconstruction, study participants are not treated with a combination of treatment types).
Exclusion Criteria:
Study Participant Criteria
- Currently enrolled in another clinical study that may interfere with treatment, assessment of recovery, or participation in this study;
- Deformities or injuries of the limb, hand, or digits that affect both the primary and secondary assessments for eligible nerve repair(s);
- History of neuropathy of any etiology, diabetic neuropathy or any other known neuropathy including compressive/traumatic neuropathies affecting the target limb;
- History of progressive neurodegenerative or autoimmune disorder affecting peripheral nerve or motor function (e.g., amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease);
- History of chronic ischemic condition of the upper extremity;
- Expected use of medication during the study that is known to impact nerve regeneration or to cause peripheral neuropathy;
- Undergoing or expected to undergo treatment with chemotherapy, radiation therapy, or other known treatment which affects the growth of neural and/or vascular systems;
Participant is unlikely to comply with all study requirements and standard medical care procedures for the duration of the study schedule;
Injury/Repair Criteria for Each Nerve
- Median nerve repairs where the ulnar nerve has been transected due to injury or repair;
- Repair(s) of a sensory-only proximal nerve stump;
- Incomplete nerve transections;
- Multilevel nerve injury pattern requiring two or more isolated reconstructions along the nerve pathway (for example, reconstruction of median nerve in forearm and recurrent motor branch resulting in repair pattern of graft to native nerve to graft to distal target);
- Inadequate soft tissue coverage or extensive soft tissue injury which will impair recovery assessment;
- Nerve avulsion injuries and nerve traction injuries resulting in rupture of the nerve;
- Replantation/amputation of the limb, hand, or digits involved in both the primary and secondary assessments for eligible nerve repair(s);
- Nerve repairs utilizing either end-to-side or side-to-side coaptation techniques;
- Nerve transfer, tendon transfer, or other concomitant treatment at the time of nerve repair that affects assessment of function of the innervated muscle organ;
- Use of coaptation devices that include metallic components or activated polymers and coaptations completed with fibrin glue only; and
- Injuries with vascular damage resulting in inadequate perfusion despite repair (i.e., both radial and ulnar arteries injured [one injured artery is allowed]).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Avance Nerve Graft
Study Treatment: Avance Nerve Graft repairs of mixed or motor nerves (> 25 mm gaps)
|
A commercially available, sterile, single-use peripheral nerve scaffold indicated for the treatment of functional deficits, manufactured from decellularized and sterilized extracellular matrix derived from human peripheral nerve tissue.
Autres noms:
|
|
Comparateur actif: Sural nerve autograft
Comparator: Sural nerve autograft repairs of mixed or motor nerves (> 25 mm gaps)
|
A patient's own peripheral nerve tissue harvested in a secondary surgical procedure of the lower extremity where a functioning sural nerve is sacrificed for use in the reconstruction of a nerve defect.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Recovery of motor function
Délai: Assessed at 24 months
|
Medical Research Council Classification (MRCC) of motor recovery score.
This is an ordinal scale from M0-M5, with grade M0 meaning no contraction and M5 meaning full recovery in all muscles.
|
Assessed at 24 months
|
|
Recovery of sensory function
Délai: Assessed at 24 months
|
Medical Research Council Classification (MRCC) of sensory recovery score.
This is an ordinal scale from S0-S4, with grade S0 meaning absence of sensibility in the autonomous area and S4 meaning complete recovery (2-point discrimination, 2-6 mm).
|
Assessed at 24 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Meaningful recovery (MR) of motor and sensory function
Délai: Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
|
Medical Research Council Classification (MRCC) of motor recovery score.
Meaningful recovery is defined as ≥ M3 MRCC of motor recovery and ≥ S3 MRCC of sensory recovery.
|
Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
|
|
Treatment response (TR) of motor and sensory function
Délai: Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
|
Medical Research Council Classification (MRCC) of motor recovery score.
Treatment response is defined as a 1-point increase in MRCC score from post-operative baseline.
|
Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
|
|
Time to MR of motor and sensory function
Délai: Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
|
Time from surgery to meaningful recovery of motor function in all repairs and of sensory function in mixed nerve repairs.
|
Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
|
|
Time to TR of motor and sensory function
Délai: Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
|
Time from surgery to treatment response of motor function in all repairs and of sensory function in mixed nerve repairs.
|
Assessed at Week 4, Month 3, Month 6, Month 9, Month 12, Month 15, Month 18, Month 21, Month 24
|
|
QuickDASH upper extremity disability score
Délai: Assessed at 24 months
|
The QuickDASH questionnaire (including Work and Sports/Performance Art modules if applicable) is a PROM questionnaire to measure physical functions and symptoms in participants with upper limb musculoskeletal disorders and will be used to assess the study participant's functional quality of life (QoL)as it pertains to the affected arm.
This 11-item questionnaire addresses arm-specific symptoms and disability during the preceding week and is used to estimate the participant's view of disability.
Each item is based on an ordinal scale from 1 to 5, where higher values are worse.
QuickDASH scores range from 0 to 100, with a score of 0 indicating no disability and a score of 100 representing the most severe disability.
|
Assessed at 24 months
|
|
Lower Extremity Functional Scale (LEFS) score
Délai: Assessed at 24 months
|
The LEFS is a valid and reliable assessment for documenting function for individuals and groups with injury or disability to the lower extremity.
It is based on the World Health Organization's model of disability and handicap and is applicable to a wide variety of participants with lower extremity orthopedic conditions, including participants with a range of disability levels, conditions, diseases, treatments, and ages.
Applicable to sural nerve autograft group only.
The LEFS consists of 20 questions, with each activity rated from 0 (extremely difficult or unable) to 4 (no difficulty).
Scores range from 0 to 80, where higher scores indicate better lower limb function.
|
Assessed at 24 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: R. Glenn Gaston, MD, OrthoCarolina Research Institute, Inc.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- ANG-CP-013
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .